It is estimated that 0.5% of all mammalian proteins have a glycosylphosphatidylinositol (GPI)-anchor. GPI-anchored proteins (GPI-APs) play key roles, particularly in embryogenesis, neurogenesis, immune response and signal transduction. Due to their involvement in many pathways and developmental events, defects in the genes involved in their synthesis and processing can result in a variety of genetic disorders for which affected individuals display a wide spectrum of 
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| MATERIALS AND METHODS
A review of the literature was made using the PubMed database and OMIM with the words GPI and glycophosphatidylinositol.
activity. Thus, as we discuss the patients' phenotypes, we will refer to the function of the proteins encoded by the affected gene and examine how its activity becomes altered by mutations.
| Phosphatidylinositol glycan class A
PIGA encodes the phosphatidylinositol glycan class A (PIGA) protein which is part of the GPI-N-acetylglucosaminyltransferase (GPI-GnT)
complex, a collection of proteins that initiates GPI biosynthesis from phosphatidylinositol (PI) and N-acetylglucosamine (GlcNAc) to form an intermediate molecule called N-acetylglucosaminyl phosphatidylinositol (GlcNAc-PI) on the cytoplasmic side of the ER. 2 Paroxysmal nocturnal hemoglobinuria (PNH) was the first disease to be associated with a GPI biosynthesis defect (PIGA). 3 In this disorder, there is complement-mediated destruction of red blood cells due to a loss of GPI-APs CD55 and CD59 on red blood cells. 2 Since this disease is not inherited, but the result of an acquired somatic mutation, it will not be further discussed in this review. The most prominent clinical features of patients with inherited PIGA mutations are intellectual deficiency and developmental delay, as well as early onset epileptic encephalopathies in which all reported patients presented with seizures within their first year of life. The majority also showed brain anomalies such as white matter atrophy and delayed myelination, dysmorphic features and neurological anomalies (references in Supporting Information). Other phenotypes such as polyhydramnios, elevated alkaline phosphatase (ALP), cardiac anomalies, dental problems, visual impairment and deafness were also seen in these patients although less frequently, and some phenotypes were reported only once such as nephrocalcinosis, short fingers or hands, and skeletal anomalies. These widespread clinical features are consistent with the findings that the PIGA protein is expressed in a wide variety of tissues including brain, liver, heart and blood cells. 4 In the 21 patients reported, about half of them died in which the cause of death was mainly due to liver failure and respiration pneumonia. Some patients also have evidence of mitochondrial dysfunction, although the mechanism for this phenomenon is not known. 4 Studies in induced pluripotent stem cells showed decreased proliferation, abnormal synapse formation, membrane depolarization and an increased susceptibility to complement-mediated cytotoxicity. 
| PIGQ
PIGQ encodes another key component of the GPI-GnT complex. Very little information was available for the patient with a PIGQ mutation.
The only description of this patient was the diagnosis of Ohtahara syndrome, with developmental delay and early onset epilepsy. 6 
| PIGY
PIGY is the smallest subunit of the GPI-GnT complex where it directly associates with the catalytic subunit PIGA. 7 In the majority of the four patients with PIGY mutations, ophthalmologic, gastrointestinal and skeletal anomalies have been reported. The four patients reported were from two different families. 8 The children from the first family (with a homozygous coding mutation) suffered from a more severe disease where many organs were affected such as the bone and the GI tract resulting in early death, whereas the phenotype of the pair from the second family (with a homozygous promoter mutation) was limited to global developmental delay and microcephaly. In the first family, the children had elevated ALP, thus PIGY mutations are a cause of hyperphosphatasia with mental retardation syndrome (type 6, HPMRS6). The mutation in the first family caused a defect in the secondary structure of the protein which affected its association with the PIGA subunit, thus explaining the more severe phenotype than in the siblings with a decreased expression of a normal protein.
| PIGC
PIGC also encodes a subunit of the GPI-GnT complex and we recently reported three individuals with PIGC mutations from two unrelated families. These individuals have a seizure disorder responding to antiepileptic drugs and severe global developmental delay or intellectual disability. ALP levels were normal. 
| PIGH
In addition to PIGA, C, P, Q and Y, the GPI-GnT complex is also composed of PIGH. Recently, a rare PIGH homozygous variant were reported in two siblings with epilepsy, microcephaly, and behavioral difficulties 11 while another PIGH homozygous mutation was found in an individual with moderate global developmental delay and autism but with only two episodes of febrile seizures occurred at the age of 17 months which did not recur. 12 Like PIGC and PIGP patients, all these patients with PIGH mutations have normal ALP.
| PIGL
The PIGL gene encodes a de-N-acetylase, an ER protein that is involved in the second step of GPI biosynthesis. Of the 10 patients described with PIGL mutations, the main features include developmental delay, seizures, dysmorphic features and cranial shape anomalies. Deafness and ophthalmologic involvement were also described, in particular colobomas, which were not reported in patients with mutations in other GPI genes. Anomalies in the neuro, heart, as well as dental, hands and feet anomalies were also reported in the majority of these patients (references in Supporting Information). Mutations in PIGL have been identified in patients with CHIME syndrome which is a disease characterized by colobomas, heart defects, ichthyosiform dermatosis, mental retardation and ear anomalies. 13 This is consistent with the prominent characteristics in all 10 patients reported in the literature. PIGL mutations, however, do not only cause CHIME syndrome. A paper by Fujiwara et al presented a patient who did not have colobomas or heart defects. Instead, the patient had only strabismus as an ophthalmological anomaly. 14 The clinical phenotype for PIGL deficiency is therefore expanding, but with the current clinical data that is available, ear anomalies and colobomas still appear to be hallmarks of this disease.
| PIGW
One of the components of the GPI structure is a glycan core that contains three mannose residues. These residues can be modified with various side chains such as ethanolamine phosphate (EtNP). PIGW encodes an inositol acyltransferase which introduces an acyl group to the inositol ring of the PI. It was also found to be required for the successful attachment of an EtNP to the third mannose of the GPI. 15 Three patients with a PIGW mutation were described in the litera- 16 With a sample size of three, it is difficult to associate clinical features that are distinct to these patients. A larger group is necessary to highlight phenotypes specific to the PIGW gene.
| PIGM
The PIGM gene encodes a mannosyltransferase enzyme which transfers the first mannose to the GPI on the luminal side of the ER (Figure 1 ). Very little data was available for the four patients with PIGM mutations. A common characteristic that is evident is that all patients suffered from seizures, particularly absence seizures. 18, 19 Similar to mutations in PIGA, PIGM mutations were found to be hypomorphic and lead to a partial loss of GPI anchor biosynthesis. 19 Further, it seems PIGM-deficient patients presented less frequently with neurologic impairment and facial dysmorphism compared to other IGD individuals.
| PIGV
The PIGV gene encodes the GPI mannosyltransferase 2 enzyme which adds the second mannose residue to the GPI anchor ( Figure 1 ). The third mannose is added by the protein encoded by the PIGB gene, not discussed in this review. It has been found in earlier studies that mutations in the PIGV gene are the major cause of Hyperphosphatasia with mental retardation syndrome 1 (HPMRS1), also known as Mabry syndrome. 20 Indeed, all the patients reported with severe intellectual disability and the majority (21/22) patients had an elevated ALP level (references in Supporting Information).
ALP is a GPI-AP found throughout the body. Studies have found that an elevated serum ALP level is a useful marker to diagnose defects in GPI genes involved in the later steps of the GPIbiosynthesis pathway. 21 The process of how this occurs involves the GPI transamidase complex, an enzyme that mediates the attachment of the GPI anchor to proteins carrying a C-terminal GPI-attachment signal. In normal conditions, the GPI transamidase cleaves the GPIattachment signal peptide on the protein and simultaneously adds the GPI moiety. In the case of PIGV mutations in which there is a lack of mature GPI synthesis, the GPI transamidase recognizes the incomplete GPI-bearing mannose and cleaves the GPI-attachment signal.
However, the signal peptide cannot be replaced with a GPI anchor, resulting in the release of non-GPI anchored soluble proteins into the serum. 21 This 
| PIGN
The PIGN gene encodes one of the three EtNP transferases which adds an EtNP to the mannose residues on GPI. The other two enzymes with this function are PIGG and PIGO. 23 PIGN adds the EtNP to the first mannose residue. 24 The clinical phenotypes observed The phenotype manifests with different severity depending on the mutation, with the more severe ones often leading to early death.
In fact, many deaths have been reported in patients with PIGN mutations compared to those with other GPI mutations: 10 patients died before the age of four, and 1 patient died at 14 years old. For six patients, the pregnancy was terminated so some clinical phenotypes could not be assessed in these individuals.
| PIGO
As mentioned, PIGO is part of the EtNP transferase enzymes. It is involved in attaching an EtNP on the third mannose of GPI in the later steps of the GPI biosynthesis pathway. This EtNP links the GPI anchor to the protein. 23 Seventeen patients with PIGO mutations were described in the literature (references in Supporting Information). In addition to intellectual deficiency and other neurological anomalies which all patients displayed, the majority presented with seizures, dysmorphic facial features, brachytelephalangy, hypoplastic nails, and anomalies in their brain structure such as cerebellar atrophy and thin corpus callosum.
Gastrointestinal anomalies were seen, with anal atresia being the predominant GI malformation. Additionally, hyperphosphatasia was reported in the majority of these patients (13/17) . This elevated ALP is caused by a similar mechanism as for patients with a PIGV mutation.
PIGO is one of the GPI genes associated with hyperphosphatasia mental retardation syndrome (HPMRS2). This disease is characterized by increased ALP, intellectual deficiency, seizures, hypotonia, and facial dysmorphic features. 25 These symptoms were present in the patients reported with PIGO mutations, but they are also present in patients with mutations in PIGV, PGAP2 and PGAP3 genes. 
| PIGT
PIGT encodes for the protein phosphatidylinositol glycan biosynthesis class T, a crucial component of the GPI transamidase complex. A study found that PNH can also occur in patients with mutations in this gene.
However, in contrast to PNH caused by the PIGA gene which requires only one somatic mutation event, a germline as well as a somatic mutation in PIGT are both needed to acquire the disease. 29 The 13 patients with PIGT mutations reported in this review does not include those with PNH. The majority of these reported individuals are severely affected; ophthalmologic, brain anomalies, and skeletal findings were noted for the majority of these patients. A few also had anomalies in other organs, including nephrocalcinosis which appeared more frequently in this cohort compared to those with mutations in other IGD genes.
30-35
Interestingly, patients with PIGT mutations had a decreased level of serum ALP. This is striking as one of the diagnostic markers for inherited GPI-anchor deficiencies is usually an elevated ALP level. 
| GPAA1
GPAA1 encodes a protein belonging to the transamidase complex which is involved in the attachment of the GPI anchor to the Cterminus of precursor proteins in the ER (Figure 1 ). Among the components of this complex, only PIGT was earlier found to be mutated in many patients as mentioned above. We reported 10 individuals from five families with bi-allelic mutations in GPAA1. Most patients with GPAA1 mutations presented with early-onset seizures, hypotonia and global developmental delay which overlapped with those identified in individuals with PIGT mutations. In addition, these patients also suffered from osteopenia and cerebellar atrophy. APs, but with a defect in their GPI-anchor structure. 36 A total of 11 patients with PGAP1 mutations are described in the literature. Most of them have intellectual disability and other neurological anomalies, and a minority has cranial shape and structural brain anomalies. Only three patients had epilepsy, which was surprising considering almost all patients with mutations in other genes of the GPI biosynthesis pathway suffered from seizures, with the exception of patients with PGAP2 mutations where less than half of the patients were affected. Furthermore, only a minority of patients had facial dysmorphism which was also unexpected as dysmorphic features were known as a common phenotype in patients with GPI disorders. 36, [39] [40] [41] [42] [43] [44] The abnormal structure of the GPI-APs' membrane anchors does not seem to translate into life-threatening phenotypes or obvious malformations in patients with mutations in the PGAP1 gene. However, affected patients still suffer severe intellectual deficiency with other neurological anomalies. Further, the patients showed normal serum levels of ALP suggesting that an elevated ALP level is not a characteristic of patients with PGAP1 mutations. This is supported by PGAP1 mouse models which showed normal ALP levels despite PGAP1 anomalies. 36 
| PGAP3
PGAP3 is expressed in the Golgi and encodes an enzyme that plays a role in fatty acid remodeling of the GPI-anchor. This modification is important for the proper association between GPI-APs and lipid rafts. 45 In the Golgi, PGAP3 proteins first remove unsaturated fatty acids from the lipid moiety of the GPI-AP. Saturated fatty acids are then attached by PGAP2 proteins.
46
Of the 28 patients with PGAP3 mutations described in the literature, few major anomalies were reported except for abnormal brain structures notably an atrophy of the temporal lobes and the corpus callosum, dysmorphic facial features and an elevated serum ALP seen in almost all patients (references in Supporting Information). This can be a characteristic feature for patients with PGAP3 mutations, and thus mutations in this gene are responsible for HPMRS4.
In patients with a PGAP3 mutation, surface levels of GPI-APs are normal. However, because their lipid structure is not remodeled, they cannot localize on lipid rafts and therefore cannot be properly sorted to the plasma membrane. 46 Additionally, the GPI-APs that manage to reach the plasma membrane are more prone to cleavage. 45 
| PGAP2
PGAP2 is involved in the maturation of the GPI anchor on GPI-APs. It is located in the Golgi and is involved in the re-acylation of the GPIanchor, the final step in the fatty-acid remodeling. This fatty acid modification is necessary for the stable association between GPI-APs and the lipid rafts that transport them to the cell surface. 47 The clinical description of patients with PGAP2 mutations is similar to patients with PGAP1 mutations in that only the minority presented with facial dysmorphism. For the 12 patients reported in this cohort, intellectual disability, severe motor developmental delay and seizures were the most predominant features. Only a minority of patients manifested additional features. 26, [48] [49] [50] Deficiency of PGAP2 affects the re-acylation step in GPI-anchor remodeling, leading to the formation of GPI-APs that lack the lipid moiety. These proteins are more prone to cleavage by phospholipase D where, after their transport to the plasma membrane, they get cleaved and released from the cell surface. 26 A consequence of this is hyperphosphatasia as GPI-APs are released from the plasma membrane. This is supported by the literature where five of the reported patients have shown an elevated ALP level (thus, mutations in this gene are responsible for HPMRS3). However, it is not a key diagnosing feature as it does not represent the majority of the cohort. Intellectual deficiency seems to be the main feature of PGAP2-deficient patients because it was present in all individuals and mutations in this gene expand the clinical spectrum of IGDs to isolated intellectual disability. 48 
| Overall analysis
The great majority of patients reported presented with developmental delay or intellectual disability. Most frequently, the patients also presented with epilepsy, although this was observed to a lesser extent in patients with mutations in genes PGAP1. Several patients also presented with additional neurologic findings, this was predominantly the case for patients with mutations in genes PIGA, PIGL, PIGG, PIGN, PIGO, PIGT, PIGV, PIGW, PIGY, PGAP1, PGAP3, PIGP and GPAA1.
Hypotonia was reported for the majority. Spasticity, rigidity, dystonia, ataxia, reflex anomalies, tremors and choreiform movements were also commonly reported.
Craniofacial dysmorphism varying from mildly dysmorphic facies to coarse features were noted, in particular for patients with mutations in PIGA, PIGG, PIGL, PIGN, PIGO, PIGP, PIGT, PIGV, PIGW, PIGY, GPAA1 and PGAP3 genes.
Hearing impairment was reported for 8 of 10 patients with PIGL mutations and in a minority of patients with PIGA, PIGO, PIGT, PIGV, PGAP2 and PGAP3 mutations, while it was not reported for other genes.
Ophthalmological anomalies were seen in a majority of individuals with PIGL, PIGP, PIGT, PIGN, PIGY and GPAA1 mutations. Colobomas were described in 8 out of 10 patients with PIGL mutations but not in patients with mutations in other genes. For the other patients, cortical visual impairment, strabismus and nystagmus were the most common findings.
As for cardiac anomalies, they were observed in the majority of Nephrocalcinosis was present in a small group of patients with PIGA (1/21), and PIGT (4/13).
As for teeth anomalies, they were present in a majority of individuals with PIGL mutations but a minority of those with PIGT, PIGV, PIGA, PIGO and PGAP3 mutations. The common teeth anomalies were widely spaced teeth, microdontia, shape anomalies and delayed eruption/absence of teeth. Other patients showed gingival hypertrophy.
Many of the patients were reported with short fingers or hands, but some were also described as having other hand and feet anomalies. Anomalies of the digits were reported for at least half of the patients with PIGV, PIGO, PIGL, PIGH and PIGY mutations, and a minority of patients with PIGA, PIGG, PIGN, and GPAA1 mutations.
The hand and feet anomalies described included deepened plantar Thus, it is important to note that the central nervous system anomalies can progress, both on imaging and clinically.
Prenatal findings were noted for a minority of patients, but were mostly unspecific: polyhydramnios, increased nuchal fold and pyelectasis. Some patients also presented with various neonatal complications such as a low APGAR score, neonatal hypotonia with feeding difficulties, breathing difficulties, hyperbilirubinemia, and hypoglycemia.
Unfortunately, serum ALP was not measured for several patients.
However, it was reported to be increased in a number of patients with mutations in PIGO, PIGV, PIGY and PGAP3 genes, and in some patients with mutations in PIGA, PIGL, PIGN, PIGW and PGAP2 genes, while patients with PIGT mutations had low levels of serum ALP. As described above, previous data suggested that the elevated serum ALP observed in some GPI-biosynthesis defects could be explained by cleavage of the signal peptide and secretion of soluble ALP because of abnormal GPI structure, 21 but this was dependent on the mannose composition of the abnormal GPI.
| Treatment
Limited therapies are available for GPI-AP deficiency. Treatment with the histone deacetylase inhibitor butyrate resolved intractable epilepsy in an individual who presented with mutations in the PIGM promoter. Lymphoblast studies showed the drug also rescued levels of the GPI-AP as it increased the expression of PIGM gene affected by the promoter mutation. 18 Since ALP is essential to allow pyridoxal-phosphate to pass through the blood-brain barrier and pyridoxine passes through the blood-brain barrier and is converted to pyridoxal-phosphate, important for GABA synthesis, pyridoxine (B6) supplementation can help 
